Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment.
作者信息
Markides Vias, Schilling Richard J
机构信息
St Mary's Hospital, London, UK.
出版信息
Heart. 2003 Aug;89(8):939-43. doi: 10.1136/heart.89.8.939.
Abstract
摘要
相似文献
1
Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment.心房颤动：分类、病理生理学、机制及药物治疗
Heart. 2003 Aug;89(8):939-43. doi: 10.1136/heart.89.8.939.
2
Relevance of atrial fibrillation classification in clinical practice.心房颤动分类在临床实践中的相关性。
J Cardiovasc Electrophysiol. 2002 Jan;13(1 Suppl):S27-30. doi: 10.1111/j.1540-8167.2002.tb01950.x.
3
Pharmacotherapy of atrial fibrillation.心房颤动的药物治疗
Asian Cardiovasc Thorac Ann. 2003 Dec;11(4):364-74. doi: 10.1177/021849230301100424.
4
Antiarrhythmic drug therapy in the treatment of atrial fibrillation.抗心律失常药物治疗心房颤动
Cardiol Clin. 1996 Nov;14(4):507-20. doi: 10.1016/s0733-8651(05)70300-3.
5
Rate versus rhythm control in atrial fibrillation.心房颤动的心率控制与节律控制
Can Fam Physician. 2013 Feb;59(2):161-8.
6
Oral d,l-sotalol in atrial fibrillation and/or flutter.口服消旋索他洛尔治疗心房颤动和/或心房扑动
Am J Cardiol. 2000 Jan 1;85(1):132-3. doi: 10.1016/s0002-9149(99)00803-6.
7
[Atrial fibrillation--update 2004].[心房颤动——2004年更新]
Ther Umsch. 2004 Apr;61(4):229-33. doi: 10.1024/0040-5930.61.4.229.
8
Pathophysiology of atrial fibrillation: insights into the renin-angiotensin system.心房颤动的病理生理学：对肾素-血管紧张素系统的见解
Arch Cardiovasc Dis. 2008 Nov-Dec;101(11-12):787-91. doi: 10.1016/j.acvd.2008.09.015. Epub 2008 Nov 20.
9
[Atrial fibrillation (the questions of etiology, classification, and treatment)].[心房颤动（病因、分类及治疗问题）]
Klin Med (Mosk). 2006;84(2):7-15.
10
[The treatment of atrial fibrillation--recent topics on the upstream therapy of atrial fibrillation].[心房颤动的治疗——心房颤动上游治疗的最新话题]
Nihon Ronen Igakkai Zasshi. 2005 Sep;42(5):535-6. doi: 10.3143/geriatrics.42.535.
引用本文的文献
1
Individuals Recovered from Severe COVID-19 are Predispose to Develop Atrial Fibrillation.从重症新冠病毒疾病中康复的个体易患心房颤动。
Int J Gen Med. 2025 Aug 12;18:4379-4390. doi: 10.2147/IJGM.S527058. eCollection 2025.
2
Role of Computational Modelling in Enhancing Thermal Safety During Cardiac Ablation.计算建模在提高心脏消融热安全性中的作用。
Interdiscip Cardiovasc Thorac Surg. 2025 Aug 5;40(8). doi: 10.1093/icvts/ivaf184.
3
Remote Ischemic Preconditioning for Electrical Cardioversion of Atrial Fibrillation-the Prospective Randomized PRECON-AF Study.用于心房颤动电复律的远程缺血预处理——前瞻性随机PRECON-AF研究
CJC Open. 2025 Mar 10;7(5):571-578. doi: 10.1016/j.cjco.2025.03.004. eCollection 2025 May.
4
A Titin Missense Variant Causes Atrial Fibrillation.一种肌联蛋白错义变体导致心房颤动。
medRxiv. 2024 Dec 8:2024.12.06.24318402. doi: 10.1101/2024.12.06.24318402.
5
Association of Atrial Fibrillation with Insomnia in the Elderly Population.心房颤动与老年人群失眠的关系。
J Prim Care Community Health. 2024 Jan-Dec;15:21501319241296623. doi: 10.1177/21501319241296623.
6
Epidemiology and clinical implications of atrial fibrillation among stroke patients in Ethiopia: a comprehensive systematic review and meta-analysis.在埃塞俄比亚，中风患者中心房颤动的流行病学和临床意义：全面的系统评价和荟萃分析。
BMC Neurol. 2024 Oct 14;24(1):391. doi: 10.1186/s12883-024-03894-8.
7
Effect of Colchicine for Prevention of Recurrent Stroke in Ischemic Stroke Patients with Atrial Fibrillation: A Randomized Double-blinded Placebo-controlled Trial.秋水仙碱对心房颤动缺血性卒中患者预防复发性卒中的作用：一项随机双盲安慰剂对照试验。
Rev Recent Clin Trials. 2025;20(1):59-67. doi: 10.2174/0115748871325292240904060109.
8
Comparison between non-vitamin K oral antagonist versus warfarin in atrial fibrillation with and without valvular heart disease: a systematic review and meta-analysis.非维生素K口服抗凝剂与华法林在伴或不伴有心脏瓣膜病的心房颤动患者中的比较：一项系统评价和荟萃分析。
Egypt Heart J. 2024 Aug 9;76(1):102. doi: 10.1186/s43044-024-00535-w.
9
Oral anticoagulation use in non-valvular atrial fibrillation patients in rural setting.农村地区非瓣膜性心房颤动患者口服抗凝药的使用情况。
Am J Med Open. 2022 Oct 13;9:100026. doi: 10.1016/j.ajmo.2022.100026. eCollection 2023 Jun.
10
Enhancing Treatment Outcomes in Atrial Fibrillation: A Contemporary Literature Review of the Impact of Optimizing Patient Well-Being in Treatment Management.改善心房颤动的治疗效果：关于在治疗管理中优化患者健康状况影响的当代文献综述
Cureus. 2024 Jun 13;16(6):e62321. doi: 10.7759/cureus.62321. eCollection 2024 Jun.
本文引用的文献
1
KCNQ1 gain-of-function mutation in familial atrial fibrillation.家族性心房颤动中的KCNQ1功能获得性突变。
Science. 2003 Jan 10;299(5604):251-4. doi: 10.1126/science.1077771.
2
A comparison of rate control and rhythm control in patients with atrial fibrillation.心房颤动患者心率控制与节律控制的比较。
N Engl J Med. 2002 Dec 5;347(23):1825-33. doi: 10.1056/NEJMoa021328.
3
Autonomic tone variations before the onset of paroxysmal atrial fibrillation.阵发性心房颤动发作前的自主神经张力变化。
Circulation. 2002 Jun 11;105(23):2753-9. doi: 10.1161/01.cir.0000018443.44005.d8.
5
Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.多非利特治疗左心室功能减退患者心房颤动-扑动的疗效：丹麦多非利特心律失常和死亡率研究（DIAMOND）子研究
Circulation. 2001 Jul 17;104(3):292-6. doi: 10.1161/01.cir.104.3.292.
6
Antithrombotic therapy in atrial fibrillation.
Chest. 2001 Jan;119(1 Suppl):194S-206S. doi: 10.1378/chest.119.1_suppl.194s.
7
Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.心房颤动的节律或心率控制——心房颤动的药物干预（PIAF）：一项随机试验。
Lancet. 2000 Nov 25;356(9244):1789-94. doi: 10.1016/s0140-6736(00)03230-x.
8
Endocardial mapping of atrial fibrillation in the human right atrium using a non-contact catheter.使用非接触式导管对人右心房房颤进行心内膜标测。
Eur Heart J. 2000 Apr;21(7):550-64. doi: 10.1053/euhj.1999.1851.
9
Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.胺碘酮预防心房颤动复发。加拿大心房颤动试验研究人员。
N Engl J Med. 2000 Mar 30;342(13):913-20. doi: 10.1056/NEJM200003303421302.
10
Are electrophysiological changes induced by longer lasting atrial fibrillation reversible? :observations using the atrial defibrillator.持续时间较长的心房颤动所引起的电生理变化是否可逆？：使用心房除颤器的观察结果
Circulation. 1999 Jul 13;100(2):113-6. doi: 10.1161/01.cir.100.2.113.
Zotero 插件